Vor Biopharma Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
Vor Biopharma Inc. (VOR) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price of $2.59 per share as of 2020-12-31, per its 10-K filed 2023-03-23.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice · last filed 2023-03-23
- 2020-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price $2.59.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2020-12-31 | $2.59 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |